Company news
Oncodesign Precision Medicine S.A. news in 2024
Oncodesign Precision Medicine S.A.'s news releases, calls and decks from 2024, newest first.
Oncodesign Precision Medicine Reacquires Rights to Its OPM-201 Program From Servier After a Positive Phase I Trial in Healthy Volunteers
December 20, 2024
OPM Reports Final Results of Its Phase 1 Study With RIPK2 Inhibitor OPM-101, With Strong Safety Data and No Cardiac Toxicity, Paving the Way for the Launch of Phase 1b/2a
October 22, 2024
OPM Announces Poster Presentation on OPM-101, a RIPK2 Kinase Inhibitor, in Healthy Volunteers at UEG Week 2024 Conference
October 15, 2024
OPM Announces Its First-half 2024 Results and Provides an Update on Its Clinical Developments, and Its Financial Situation
September 25, 2024
OPM Announces Positive Results of Its Phase 1 in Healthy Volunteers with OPM-101: Strong Target Engagement With Excellent Safety Profile
July 16, 2024
Oncodesign Precision Medicine (OPM) obtains €5.6 million in public funding for its DEMOCRITE program dedicated to the clinical development of OPM-101
April 17, 2024